Data / Form D filings / Clovis Oncology, Inc.
Clovis Oncology, Inc.: Form D filings
Clovis Oncology, Inc., a pharmaceuticals company in Boulder, CO, filed 5 Form D notices with the SEC between 2009 and 2013. The latest, on November 27, 2013, reports $192 million sold of an offering with no set size to 9 investors.
Find out what Clovis Oncology, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2525 28TH STREET, SUITE 100, Boulder, CO, 80301
- Phone
- (303) 625-5000
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2009
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1466301
The full lists. Form D filings in Colorado: 1,787 rows, $89.35, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 27, 2013 | New notice | Indefinite | $191,962,756 | Indefinite | 9 | Nov 19, 2013 | sec.gov |
| Jun 2, 2011 | New notice | Indefinite | $20,000,000 | Indefinite | 18 | May 25, 2011 | sec.gov |
| May 18, 2011 | Amendment | $146,300,000 | $146,300,000 | $0 | 19 | May 15, 2009 | sec.gov |
| May 19, 2010 | New notice | $146,300,000 | $146,300,000 | $0 | 19 | May 15, 2009 | sec.gov |
| Jun 25, 2009 | New notice | $146,300,000 | $146,300,000 | $0 | 19 | May 15, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Gillian C. Ivers-Read | Executive Officer | |
| Paul C. Klingenstein | Director | |
| James C. Blair | Director | |
| Steven L. Hoerter | Executive Officer | |
| Brian G. Atwood | Director | |
| M. James Barret | Director | |
| Keith L. Flaherty | Director | |
| Patrick J. Mahaffy | Executive Officer, Director | |
| Erle T. Mast | Executive Officer | |
| Thorlef J. Spickschen | Director | |
| Ginger L. Graham | Director | |
| Andrew R. Allen | Executive Officer | |
| Edward J. McKinley | Director |
Every Form D from the week of Nov 25, 2013 · All recent filings in Colorado · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Clovis Oncology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.